CN1138786C - 识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途 - Google Patents

识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途 Download PDF

Info

Publication number
CN1138786C
CN1138786C CNB988004771A CN98800477A CN1138786C CN 1138786 C CN1138786 C CN 1138786C CN B988004771 A CNB988004771 A CN B988004771A CN 98800477 A CN98800477 A CN 98800477A CN 1138786 C CN1138786 C CN 1138786C
Authority
CN
China
Prior art keywords
obm
protein
cells
ocif
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988004771A
Other languages
English (en)
Chinese (zh)
Other versions
CN1222917A (zh
Inventor
ɽ�ھ���
山口京二
�˱�Т
保田尚孝
中川信明
岛伸行
木野崎雅彦
津田英资
后藤雅昭
矢野和树
������֦
友保昌拓
小林文枝
鹫田尚洋
高桥研
森永伴法
东尾侃二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1138786(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1222917A publication Critical patent/CN1222917A/zh
Application granted granted Critical
Publication of CN1138786C publication Critical patent/CN1138786C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
CNB988004771A 1997-04-15 1998-04-15 识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途 Expired - Lifetime CN1138786C (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
JP97808/97 1997-04-15
JP97808/1997 1997-04-15
JP9780897 1997-04-15
JP15143497 1997-06-09
JP151434/1997 1997-06-09
JP151434/97 1997-06-09
JP21897/1997 1997-08-12
JP217897/97 1997-08-12
JP21789797 1997-08-12
JP224803/1997 1997-08-21
JP224803/97 1997-08-21
JP22480397 1997-08-21
JP332241/97 1997-12-02
JP33224197 1997-12-02
JP33224/1997 1997-12-02

Publications (2)

Publication Number Publication Date
CN1222917A CN1222917A (zh) 1999-07-14
CN1138786C true CN1138786C (zh) 2004-02-18

Family

ID=27525882

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988004771A Expired - Lifetime CN1138786C (zh) 1997-04-15 1998-04-15 识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途

Country Status (21)

Country Link
US (7) US7527790B2 (enExample)
EP (3) EP2336168A1 (enExample)
JP (7) JP3523650B2 (enExample)
KR (1) KR100496063B1 (enExample)
CN (1) CN1138786C (enExample)
AT (1) ATE328006T1 (enExample)
AU (1) AU735355B2 (enExample)
CA (2) CA2781623A1 (enExample)
CY (1) CY2010017I2 (enExample)
DE (2) DE69834699T3 (enExample)
DK (1) DK0911342T4 (enExample)
ES (1) ES2263204T5 (enExample)
FR (1) FR10C0048I2 (enExample)
HU (3) HU229476B1 (enExample)
IL (1) IL127115A (enExample)
LU (1) LU91759I2 (enExample)
NO (2) NO322632B1 (enExample)
NZ (1) NZ332995A (enExample)
PT (1) PT911342E (enExample)
RU (1) RU2238949C2 (enExample)
WO (1) WO1998046644A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
DE69834699T3 (de) 1997-04-15 2013-11-14 Daiichi Sankyo Co., Ltd. Neues protein und verfahren zu dessen herstellung
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2284203T5 (es) * 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
TW529954B (en) 1998-10-28 2003-05-01 Sankyo Co Agent for treating abnormal bone metabolism
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
MXPA02008144A (es) † 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
AU2002253133B2 (en) 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
CA2508773C (en) * 2002-12-10 2013-08-27 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (ru) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Способ профилактики рождения больных остеопетрозом детей
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1991694T3 (da) * 2006-02-13 2016-08-01 Fluidigm Canada Inc Genekspressionsanalyse med grundstoftagget oligonukleotid
WO2007132512A1 (ja) 2006-05-12 2007-11-22 Keio University 炎症性疾患の検出並びに炎症性疾患の予防又は治療用組成物
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
KR101235439B1 (ko) 2006-10-11 2013-02-20 오리엔탈 이스트 컴파니 리미티드 가용형 ｒａｎｋｌ과 에피토프 태그의 융합 단백질을 포함하는 시약
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
JP5191487B2 (ja) 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 新しい骨量増加薬
EP2206727B1 (en) 2007-10-11 2015-04-01 Daiichi Sankyo Company, Limited ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
WO2010053610A2 (en) * 2008-07-30 2010-05-14 Emergent Biosolutions, Inc. Stable anthrax vaccine formulations
EP2343087B1 (en) 2008-09-30 2018-07-18 Oriental Yeast Co., Ltd. Novel inducer of chondrocyte proliferation and differentiation
US20120018338A1 (en) * 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
NZ593550A (en) 2009-04-09 2013-11-29 Daiichi Sankyo Co Ltd ANTI-Siglec-15 ANTIBODY
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
CN103237813A (zh) 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体
WO2012050154A1 (ja) * 2010-10-13 2012-04-19 学校法人 東京女子医科大学 抗vdac抗体を含有する破骨細胞形成抑制剤
JPWO2012133914A1 (ja) 2011-03-31 2014-07-28 オリエンタル酵母工業株式会社 Ｒａｎｋｌアンタゴニストを含む癌免疫増強剤
US10420801B2 (en) 2012-03-21 2019-09-24 The General Hospital Corporation Isolation and use of human lymphoid organ-derived suppressive stromal cells
JP6059205B2 (ja) 2012-03-30 2017-01-11 第一三共株式会社 ＣＤＲ改変抗Ｓｉｇｌｅｃ−１５抗体
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
JP6599861B2 (ja) 2013-08-07 2019-10-30 リグスホスピタレット コペンハーゲン ユニバーシティ ホスピタル 男性不妊治療用の抗体、化合物、およびその誘導体
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
WO2018052153A1 (ko) * 2016-09-13 2018-03-22 주식회사 이앤에스헬스케어 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN112521466B (zh) * 2020-01-22 2022-06-17 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0192658A4 (en) 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3356775B2 (ja) * 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118119C (en) 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2171610A1 (en) 1993-09-14 1995-03-23 Gideon A. Rodan Cdna encoding a novel human protein tyrosine phosphatase
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
EP0727211A1 (en) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
CA2274987C (en) * 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE69834699T3 (de) * 1997-04-15 2013-11-14 Daiichi Sankyo Co., Ltd. Neues protein und verfahren zu dessen herstellung
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
WO1998049305A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) * 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
DE69939822D1 (de) 1998-05-14 2008-12-11 Immunex Corp Verfahren zur hemmung der wirkung der osteoklasten
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
ES2287028T3 (es) 1999-09-03 2007-12-16 Amgen Inc. Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
NZ530765A (en) * 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Also Published As

Publication number Publication date
JP4878616B2 (ja) 2012-02-15
AU6851898A (en) 1998-11-11
EP0911342B2 (en) 2013-05-22
DE69834699T3 (de) 2013-11-14
LU91759I2 (fr) 2011-01-24
NO2010021I2 (no) 2015-03-09
AU735355C (en) 1998-11-11
JP4355357B2 (ja) 2009-10-28
JP2004041195A (ja) 2004-02-12
DK0911342T3 (da) 2006-08-21
HUP0000717A2 (hu) 2000-06-28
US20100136011A1 (en) 2010-06-03
HU229841B1 (en) 2014-09-29
NZ332995A (en) 2000-07-28
CN1222917A (zh) 1999-07-14
DK0911342T4 (da) 2013-07-29
DE69834699T2 (de) 2007-05-16
HUS1400027I1 (hu) 2016-10-28
EP2336168A1 (en) 2011-06-22
US20120329671A1 (en) 2012-12-27
NO985848D0 (no) 1998-12-14
US20050003457A1 (en) 2005-01-06
US20030176647A1 (en) 2003-09-18
FR10C0048I1 (enExample) 2011-01-14
JP4230993B2 (ja) 2009-02-25
KR100496063B1 (ko) 2005-06-21
EP0911342B1 (en) 2006-05-31
CY2010017I2 (el) 2012-01-25
CA2257247C (en) 2012-09-11
NO985848L (no) 1999-02-15
US7192718B2 (en) 2007-03-20
US7527790B2 (en) 2009-05-05
EP1657255B1 (en) 2014-07-30
ATE328006T1 (de) 2006-06-15
US7449185B2 (en) 2008-11-11
NO322632B1 (no) 2006-11-06
KR20040004509A (ko) 2004-01-13
US20030208045A1 (en) 2003-11-06
NO2010021I1 (no) 2011-01-10
JP2009029834A (ja) 2009-02-12
ES2263204T5 (es) 2013-10-14
JP3523650B2 (ja) 2004-04-26
HU229476B1 (en) 2014-01-28
JP2012041345A (ja) 2012-03-01
CY2010017I1 (el) 2011-02-02
IL127115A (en) 2013-08-29
LU91759I9 (enExample) 2019-01-02
JP2009013177A (ja) 2009-01-22
US20050208580A1 (en) 2005-09-22
US20070009520A1 (en) 2007-01-11
JP5593407B2 (ja) 2014-09-24
EP1657255A1 (en) 2006-05-17
US20080187540A9 (en) 2008-08-07
DE69834699D1 (de) 2006-07-06
RU2238949C2 (ru) 2004-10-27
CA2257247A1 (en) 1998-10-22
WO1998046644A1 (fr) 1998-10-22
JP2005176847A (ja) 2005-07-07
IL127115A0 (en) 1999-09-22
JP3935861B2 (ja) 2007-06-27
JP2013139465A (ja) 2013-07-18
ES2263204T3 (es) 2006-12-01
JP5285751B2 (ja) 2013-09-11
HU0800628D0 (en) 2010-06-28
EP0911342A1 (en) 1999-04-28
PT911342E (pt) 2006-08-31
CA2781623A1 (en) 1998-10-22
DE122010000049I1 (de) 2011-05-05
AU735355B2 (en) 2001-07-05
FR10C0048I2 (fr) 2013-08-16
EP0911342A4 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
CN1138786C (zh) 识别破骨细胞形成抑制因子结合蛋白的抗体及制备和用途
CN1263507C (zh) April受体(bcma)及其用途
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN1823163A (zh) 针对胰岛素样生长因子ⅰ受体的抗体及其应用
CN1688604A (zh) 重组抗骨桥蛋白抗体及其用途
CN1639193A (zh) 抗成纤维细胞生长因子23的抗体
CN1768076A (zh) 淀粉样β(1－42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
CN1622958A (zh) 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体
CN1189190A (zh) 抗人白介素－5受体α链的抗体
CN1407993A (zh) 基因重组抗体及其抗体片段
CN1263556A (zh) 抗gpiib/iiia重组抗体
CN1541224A (zh) 拮抗性抗-hTNFSF13b人抗体
CN1264427A (zh) osteoprotegerin结合蛋白和受体
CN1252810A (zh) 抑制凝血的抗体及其使用方法
CN1308451C (zh) 肿瘤坏死因子相关配基
CN1839157A (zh) 抗白介素－22抗体及其应用
CN1513000A (zh) 抗骨桥蛋白抗体及其用途
CN1832964A (zh) 用结合脑钠尿肽前体分子氨基酸41－46的单克隆抗体检测脑钠尿肽前体分子的方法
CN1685236A (zh) N－11端截短的β－淀粉样蛋白的单克隆抗体、组合物、方法和用途
CN1575303A (zh) 人cdr－移植抗体及其抗体片段
CN1283662C (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1589403A (zh) 测定结缔组织生长因子的方法
CN1493597A (zh) 分离树突状细胞膜蛋白基因
CN1642983A (zh) 抗C5aR抗体及其应用
CN1253471C (zh) Cc型趋化因子样蛋白质

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SANKYO CO., LTD.

Free format text: FORMER OWNER: SNOW BRAND MILK PRODUCTS CO., LTD.

Effective date: 20011204

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20011204

Address after: Tokyo, Japan

Applicant after: Sankyo Co., Ltd.

Address before: Hokkaido, Sapporo, Japan

Applicant before: Snow Brand Milk Products Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.12.02 JP 332241/1997

False: 1997.12.02 JP 33224/1997

Number: 7

Page: 398

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.12.02 JP 332241/1997

False: 1997.12.02 JP 33224/1997

Number: 7

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1997.12.2 JP 33224/1997 TO: 1997.12.2 JP 332241/1997

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1997.12.2 JP 33224/1997 TO: 1997.12.2 JP 332241/1997

CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 1997.12.02 JP 332241/1997

False: 1997.12.02 JP 33224/1997

Number: 7

Volume: 20

CI03 Correction of invention patent

Correction item: Priority

Correct: 1997.12.02 JP 332241/1997

False: 1997.12.02 JP 33224/1997

Number: 7

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: PRIORITY; FROM: 1997.12.2 JP 33224/1997 TO: 1997.12.2 JP 332241/1997

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: 1997.12.2 JP 33224/1997 TO: 1997.12.2 JP 332241/1997

C56 Change in the name or address of the patentee

Owner name: FIRST SANKYO CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SANKYO CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: Sankyo Co.

Address before: Tokyo, Japan

Patentee before: Sankyo Co., Ltd.

CX01 Expiry of patent term

Granted publication date: 20040218

CX01 Expiry of patent term